• Sabra Health Care REIT, Inc. has released its fourth-quarter and full-year 2025 results, reporting full-year revenue of US$774.63 million and net income of US$155.61 million, alongside 2026 earnings guidance of US$0.60–US$0.64 in net income per diluted share.
• While quarterly net income and earnings per share eased year on year, the company grew full-year revenue and net income and maintained a quarterly dividend of US$0.30 per share, highlighting a focus on income generation for shareholders.
• We will now examine how Sabra’s 2026 earnings guidance and continued dividend payout affect its existing investment narrative and risk profile.

Uncover the next big thing with 27 elite penny stocks that balance risk and reward.

Sabra Health Care REIT Investment Narrative Recap

To own Sabra, you need to be comfortable with a healthcare REIT that leans on long term demand for senior care, while managing operator and reimbursement risk. The latest results show full year revenue and net income growth, but softer quarterly earnings, and 2026 net income guidance of US$0.60–US$0.64 per share does not materially change the near term focus on tenant health and dividend sustainability as the key catalyst and risk.

The reaffirmed US$0.30 quarterly dividend, in place again for February 2026, is the most relevant announcement here because it keeps income front and center for shareholders while payout ratio concerns linger. Against 2026 earnings guidance and expected low single digit Cash NOI growth, this ongoing cash return underscores why many investors will be paying close attention to how well Sabra’s operators perform and how reliably rent flows through to support that dividend.

Yet investors should be aware that a high payout ratio and any pressure on tenant coverage could still lead to...

Sabra Health Care REIT's narrative projects $952.0 million revenue and $224.6 million earnings by 2028. This requires 9.1% yearly revenue growth and about a $42.3 million earnings increase from $182.3 million today.

Uncover how Sabra Health Care REIT's forecasts yield a $20.82 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community value Sabra between US$11.59 and US$49.73 per share, showing very different expectations. You can weigh these against the current focus on dividend sustainability and operator performance to judge how resilient Sabra’s story might be under different conditions.

Explore 3 other fair value estimates on Sabra Health Care REIT - why the stock might be worth over 2x more than the current price!

Build Your Own Sabra Health Care REIT Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Sabra Health Care REIT research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Sabra Health Care REIT research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sabra Health Care REIT's overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 24 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 86 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 55 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.